{"nctId":"NCT00978627","briefTitle":"Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes","startDateStruct":{"date":"2009-08"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"count":548,"armGroups":[{"label":"IDegAsp OD","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec/insulin aspart","Drug: insulin aspart"]},{"label":"IDet","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin detemir","Drug: insulin aspart"]}],"interventions":[{"name":"insulin degludec/insulin aspart","otherNames":[]},{"name":"insulin detemir","otherNames":[]},{"name":"insulin aspart","otherNames":[]},{"name":"insulin aspart","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* FOR THE MAIN TRIAL, NN5401-3594:\n* Type 1 diabetes mellitus for at least 12 months\n* Ongoing daily treatment with insulin (in a basal bolus regimen, premix insulin regimen, self mix regimen) for at least 12 months\n* HbA1c 7.0-10.0% (both inclusive)\n* BMI (Body Mass Index) below or equal to 35.0 kg/m\\^2\n* FOR THE EXTENSION TRIAL, NN5401-3645:\n* The subject must have completed the six-month treatment period in trial NN5401-3594\n\nExclusion Criteria:\n\n* FOR THE MAIN TRIAL, NN5401-3594:\n* Treatment with other insulin regimens than insulin in a basal bolus regimen/premix insulin regimen/self mix regimen within 3 months\n* Cardiovascular disease within the last 6 months\n* Uncontrolled treated/untreated severe hypertension\n* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements\n* Cancer and medical history of cancer\n* FOR THE EXTENSION TRIAL, NN5401-3645:\n* Anticipated significant lifestyle changes during the trial\n* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment","description":"Change from baseline in HbA1c after 26 weeks of treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","spread":"0.83"},{"groupId":"OG001","value":"-0.68","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Main Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3917","spread":null},{"groupId":"OG001","value":"4434","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26","description":"Overall mean of 9-point SMPG at 26 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"2.2"},{"groupId":"OG001","value":"8.4","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment","description":"Change from baseline in HbA1c after 52 weeks of treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":"0.81"},{"groupId":"OG001","value":"-0.56","spread":"0.80"}]}]}]},{"type":"PRIMARY","title":"Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol /L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3183","spread":null},{"groupId":"OG001","value":"3673","spread":null}]}]}]},{"type":"PRIMARY","title":"Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 a.m.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"309","spread":null},{"groupId":"OG001","value":"541","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 a.m.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"371","spread":null},{"groupId":"OG001","value":"572","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Trial (Secondary Endpoint): Change in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment","description":"Change from baseline in FPG after 52 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.83","spread":"5.69"},{"groupId":"OG001","value":"-2.40","spread":"5.86"}]}]}]},{"type":"PRIMARY","title":"Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)","description":"Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"408","spread":null},{"groupId":"OG001","value":"442","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"282","spread":null},{"groupId":"OG001","value":"311","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":46,"n":362},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Hypoglycaemia","Headache","Influenza"]}}}